Theranostics for Personalized Medicine Agenda

Registration

Developing Theranostics for Personalised Medicine of Infection: Opportunities, Roadblocks and Solutions
Herman Goossens, Professor, University of Antwerp, Belgium

Theranostics provide great opportunities to identify the pathogen and the correct drug to be given. The technology is changing rapidly, but most of these new technologies have not yet found applications in clinical diagnostics. Therefore, we need new initiatives that bring together a multidisciplinary team of researchers aligned towards the goal of developing successful theranostics.

The Novel Theranostic Biosensing System for the Evaluation of Therapeutic Molecules Toward the Amyloid-Forming Neurodegenerative Disease Causative Proteins
Koji Sode, Chair, Tokyo University of Agriculture and Technology, Japan

I report the novel biomonitoring system for the amyloid forming protein cytotoxicity evaluation, which is being utilized for both diagnosis of the sample toxicity and therapeutic reagent evaluation. As a model of amyloid forming protein, the evaluation of the cytotoxicity of various a-synuclein variants, the causative protein of Parkinson’s disease, is being introduced.

Coffee Break and Networking in Main Exhibition Hall

Microfluidic and Transducer Technologies for Lab on a Chip Applications
Daniel Hill, Project Coordinator, Universitat De Valencia, Spain

Recent developments of Lab on Chip technologies are presented with a special emphasis on those based on photonics sensors. In introducing the European Projects where they have taken place we show how they could be used to personalize medicine.

Standardised Microsystem Platforms for Proteomic and Genomic Analysis for Screening of Specific Diseases
Ciara Sullivan, Research Professor, University Rovira I Virgili, Spain

Integrated microsystems for detection of autoantibodies and HLA typing with a common footprint and electromechanical interface with a lightweight instrument with embedded communication abilities for direct transfer of test result to the electronic patient record on a health information system are presented.

Lunch and Networking in Main Exhibition Hall

Poster Presentations

Integration of Nucleic Acid, Protein and Small Molecule Detection on a Rapid, Point-of-Care Multi-Parameter Platform
Edward Blair, Executive Chair, Integrated Magnetics Systems Limited, United Kingdom

A demonstrator of the Scottish Enterprise Biosensor Platform (BSP) can run protein and nucleic acid diagnostics in parallel in about 10 minutes. Key to this is the integration of sample preparation, analyte process and signal detection modules through novel microfluidics.

Coffee Break and Networking in Main Exhibition Hall

Magnetic Polymersomes for Theranostics in Cancer
Sebastien Lecommandoux, Professor, Universite de Bordeaux, France

The controlled release of doxorubicin by radio-frequency magnetic hyperthermia from multifunctional magnetic polymersomes is demonstrated, showing the viability of the concept of magneto-chemotherapy in cancer. This research is developed in the framework of a FP7 European project named “Nanother”.

The Role of POCT in Theranostics; Innovation from Philips
Jeroen Nieuwenhuis, Technology Director, Philips Healthcare Incubator, Switzerland

Improving therapy compliance offers an opportunity to increase drug efficacy and improve treatment outcomes. Point-of-care immunoassays can play a key role in making this happen. An open diagnostic platform strategy will be discussed to enable a win-win for pharma and patient.

Biomarkers in Early Development
Hans Winkler, Senior Director and Global Head, Johnson & Johnson, Belgium

In early development, two types of biomarkers are important: - Pharmacodynamic markers to assess compound activity in humans (phase I) and to provide quantitative data supporting Phase II transition and dose selection. - Predictive markers to assess identification of patient populations that receive a high level of clinical benefit. For these, the development of robust assays early on is critical.

Close of Day One

Next Generation Biosensors – Technologies to Link Therapy with Diagnostics
Frank Bier, Director, Fraunhofer Institute for Biomedical Engineering, Germany

To bring diagnostics to the point of need, various technologies have to be merged to facilitate accurate measurement of molecular parameters. This is achieved by the construction of autonomous biosensors.

Coffee and Networking in Main Exhibition Hall

A Smart Miniaturized System for Isolation and Characterization of Single Circulating Tumor Cells
Liesbet Lagae, Group Leader, IMEC, Belgium

Personalised Therapy for Smoking Cessation Using a Theranostic Test
Robert Walton, Clinical Professor, Barts and The London School of Medicine and Dentistry, United Kingdom

Current theranostic tests address small volume applications. Substantial opportunity exists to improve effectiveness of therapy for common conditions if appropriate platforms can be developed.

Lunch and Networking in Main Exhibition Hall

Poster Presentations

Multi-Panel Nano-Bio-Sensing Platform for Drugs Monitoring in Personalized Therapy
Sandro Carrara, Senior Research Scientist, Swiss Federal Institute of Technology, Switzerland

In personalized medicine, drugs monitoring in patient blood is of key importance to improve the efficacy of drug treatments in many diseases. This invited talk presents innovative nano/bio/CMOS technologies required in low-cost devices for monitoring patients’ drug-metabolism.

Protease Sensing Technology for Periodontal Disease Monitoring
Steffi Krause, Reader, Queen Mary University of London, United Kingdom

Generic sensor materials for the detection of proteases have been developed and integrated into a disposable capillary fill biosensor interrogated by impedance measurements. The sensor technology is currently developed into a chair side diagnostic tool for monitoring periodontal disease.

Coffee and Networking in Main Exhibition Hall

The Impact of Systemic Chemotherapy on Molecular Profiles of Circulating Epithelial Tumor Cells (CETC) in Breast Cancer
Katharina Pachmann, Senior Scientist, Universitätsklinikum Jena, Germany

Monitoring CETC provides the earliest and most reliable indicator of successful treatment. It also, for the first time, allows monitoring of therapy effect on individual circulating tumor cells and help to reveal mechanisms situation involved in relapse.

Charles Swanton, Group Leader, Translational Cancer Therapeutics, Cancer Research UK
Charles Swanton, Researcher, Cancer Research UK, United Kingdom

Close of Conference